Author + information
- Received January 28, 2014
- Revision received March 21, 2014
- Accepted April 4, 2014
- Published online December 1, 2014.
- Daniala L. Weir, BSc∗,‡,
- Finlay A. McAlister, MD, MSc†,
- Ambikaipakan Senthilselvan, PhD∗,
- Jasjeet K. Minhas-Sandhu, MSc‡ and
- Dean T. Eurich, PhD∗,‡∗ ()
- ∗School of Public Health, University of Alberta, Edmonton, Alberta, Canada
- †Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada
- ‡ACHORD, 2-040 Li Ka Shing Center, University of Alberta, Edmonton, Alberta, Canada
- ↵∗Reprint requests and correspondence:
Dr. Dean T. Eurich, 2-040 Li Ka Shing Center for Health Research Innovation, University of Alberta, 8602 112 Street, Edmonton, Alberta T6G 2E1, Canada.
Objectives The study objective was to evaluate the effects of sitagliptin in patients with type 2 diabetes (T2D) and heart failure (HF).
Background There is uncertainty in the literature about whether dipeptidyl peptidase (DPP)-4 inhibitors cause harm in patients with HF and T2D.
Methods We analyzed data from a national commercially insured U.S. claims database. Patients with incident HF were identified from individuals with T2D initially treated with metformin or sulfonylurea and followed over time. Subjects subsequently using sitagliptin were compared with those not using sitagliptin in the 90 days before our primary outcome of all-cause hospital admission or death using a nested case-control analysis after adjustment for demographics and clinical and laboratory data. HF-specific hospital admission or death also was assessed.
Results A total of 7,620 patients with diabetes and incident HF met our inclusion criteria. Mean (SD) age was 54 years (9), and 58% (3,180) were male. Overall, 887 patients (12%) were exposed to sitagliptin therapy (521 patient years of exposure) after incident HF. Our primary composite endpoint occurred in 4,137 patients (54%). After adjustment, sitagliptin users were not at an increased risk for the primary endpoint (7.1% vs. 9.2%, adjusted odds ratio [aOR]: 0.84, 95% confidence interval [CI]: 0.69 to 1.03) or each component (hospital admission 7.5% vs. 9.2%, aOR: 0.93, 95% CI: 0.76 to 1.14; death 6.9% vs. 9.3%, aOR: 1.16, 95% CI: 0.68 to 1.97). However, sitagliptin use was associated with an increased risk of HF hospitalizations (12.5% vs. 9.0%, aOR: 1.84, 95% CI: 1.16 to 2.92).
Conclusions Sitagliptin use was not associated with an increased risk of all-cause hospitalizations or death, but was associated with an increased risk of HF-related hospitalizations among patients with T2D with pre-existing HF.
Ms. Weir is supported through graduate studentships from the Canadian Institutes of Health Research and Alberta Innovates Health Solutions (AIHS). Dr. McAlister is a Health Scholar with AIHS; and holds the University of Alberta/Capital Health Chair in Cardiovascular Outcomes Research. Dr. Eurich is a population health investigator with AIHS; and a new investigator with the Canadian Institutes of Health Research. All other authors have reported they have no relationships relevant to the contents of this paper to disclose.
- Received January 28, 2014.
- Revision received March 21, 2014.
- Accepted April 4, 2014.
- American College of Cardiology Foundation